Literature DB >> 840551

Ductus arteriosus dilatation by prostaglandin E1 in infants with pulmonary atresia.

M A Heymann, A M Rudolph.   

Abstract

Infants with pulmonary atresia depend on patency of the ductus arteriosus for survival in the immediate postnatal period. Despite continuing hypoxemia after birth the ductus arteriosus usually constricts, thus reducing pulmonary blood flow. This often occurs while awaiting surgical palliation or correction, leading either to marked deterioration in the infant's condition, or death. In ten infants with pulmonary atresia, we infused prostaglandin E1 (PGE1) at a rate of 0.1 mug/kg/min in six and 0.05 mug/kg/min in four into the descending aorta at the orifice of the ductus arteriosus. The ductus arteriosus was effectively dilated; at the narrowest point the diameter, measured in eight infants, almost doubled. In all ten infants arterial blood PO2 increased, averaging 24.6 mm Hg before and 43.7 mm Hg after the infusion was started. Infusion of PGE1 directly into the aorta adjacent to the ductus arteriosus avoided the complications of pyrexia, muscular twitching, and excitability which may be related to the effects of prostaglandins on the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 840551

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

Review 1.  Surgical management of congenital heart defects: current trends.

Authors:  P S Chopra; P S Rao
Journal:  Indian J Pediatr       Date:  1991 Sep-Oct       Impact factor: 1.967

2.  Activation of the EGFR/p38/JNK pathway by mitochondrial-derived hydrogen peroxide contributes to oxygen-induced contraction of ductus arteriosus.

Authors:  Zhigang Hong; Jésus A Cabrera; Saswati Mahapatra; Shelby Kutty; E Kenneth Weir; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2014-06-08       Impact factor: 4.599

Review 3.  Pharmacologic manipulation of the ductus arteriosus in the neonate: a physiologic basis and current state of the art.

Authors:  S K Sanyal; A Abu-Melha
Journal:  Indian J Pediatr       Date:  1988 Jan-Feb       Impact factor: 1.967

4.  Administration of E-type prostaglandins in ductus-dependent congenital heart disease.

Authors:  E D Silove
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

5.  Present status of surgery in congenital heart disease.

Authors:  P S Rao
Journal:  Indian J Pediatr       Date:  1981 May-Jun       Impact factor: 1.967

6.  Use of saphenous vein allografts for aortopulmonary artery anastomoses in neonates with complex cyanotic congenital heart disease.

Authors:  D Danilowicz; R G Ishmael; E F Doyle; O W Isom; S B Colvin; M A Greco
Journal:  Pediatr Cardiol       Date:  1984 Jan-Mar       Impact factor: 1.655

7.  Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia.

Authors:  M Tohyama; A Baba; T Tsuno; K Aonuma; A Komiyama
Journal:  Eur J Pediatr       Date:  1993-11       Impact factor: 3.183

8.  Maintaining patency of the ductus-arteriosus for palliation of cyanotic congenital cardiac malformations. The use of prostaglandin E1 and formaldehyde infiltration of the ductal wall.

Authors:  J Hatem; R M Sade; J K Upshur; A R Hohn
Journal:  Ann Surg       Date:  1980-07       Impact factor: 12.969

9.  Response to prostaglandin E1 in neonates with intracranial arteriovenous malformation treated for suspected congenital heart disease.

Authors:  R F Covert
Journal:  Pediatr Cardiol       Date:  1994 Mar-Apr       Impact factor: 1.655

10.  Prostaglandin E1 infusion in newborns with hypoplastic left ventricle and aortic atresia.

Authors:  A R Hastreiter; R L van der Horst; B Sepehri; I W DuBrow; E A Fisher; S Levitsky
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.